Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Pulse Biosciences, Inc.NASDAQ: PLSE

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$24.4M, compared with -$18.9M a year earlier. Trailing-twelve-month EBITDA was -$79.6M.

Context

  • EBITDA amounted to 20488.6% of revenue in FY2025.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$71.68M (+0.0%) for the fiscal year ending Dec 2026, a step up from the -36.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$24.4M-29.2% QoQ
Last fiscal yearDec 2025
-$71.71M-36.8% YoY
LTMJun 2026
-$79.6M-19.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.2%-15.0%+14.1 pp
1 year-36.8%+0.0%+36.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(71.71M) USD
Year-over-year change
-36.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.0% is the 4th highest of 11, against a peer median of -95.2%.
  • EBITDA amounts to 6717.4% of revenue for PLSE, versus a peer median of 105.2%.
PLSE Competitors
EBITDA for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STAASTAAR Surgical CompanyLTM Apr 2026-$4.11M USD+87.8%—1.4%
LFMDLifeMD, Inc.LTM Mar 2026-$4.22M USD-227.5%—1.9%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$29.53M USD+74.2%—1550.9%
OPKOPKO Health, Inc.LTM Mar 2026-$34.69M USD-123.1%—6.0%
BBNXBeta Bionics, Inc.LTM Mar 2026-$63.5M USD+7.9%—57.6%
PLSEPulse Biosciences, Inc.LTM Jun 2026-$79.6M USD-19.0%—6717.4%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026-$128M USD-87.3%—152.9%
NKTRNektar TherapeuticsLTM Jun 2026-$134.39M USD-53.9%—246.2%
NVCRNovoCure LimitedLTM Mar 2026-$155.38M USD-103.1%—23.0%
IMTXImmatics N.V.LTM Mar 2026-€202.4M EUR-4407.9%—542.7%
ATAIAtai Beckley Inc.LTM Jun 2026-$679.22M USD-533.9%—15185.0%
Peer median (excluding PLSE) —-95.2%—105.2%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.42M700K00350K
Cost of Revenue1.97M11.94M1.21M01.61M
Gross Profit(550K)(11.24M)(1.21M)0(1.26M)
Gross Margin-38.8%-1606.3%——-360.0%
Research & Development28.64M20.84M27.8M32.34M44.72M
Selling, General & Admin33.82M25.97M15.78M23.92M32.03M
Operating Expenses62.46M46.81M42.37M56.26M75.68M
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
EBITDA(62.51M)(57.15M)(39.9M)(52.41M)(71.71M)
EBITDA Margin-4408.6%-8164.3%——-20488.6%
Operating Income(63.01M)(58.06M)(43.57M)(56.26M)(76.94M)
Operating Margin-4443.9%-8293.9%——-21982.6%
Interest Income002.46M2.67M4.21M
Interest Expense646K448K1.1M00
Other Income / Expenses(646K)(448K)1.36M2.67M4.16M
Income Before Tax(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Pre-Tax Margin-4489.4%-8357.9%——-20794.6%
Income Tax Expense00000
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Net Margin-4489.4%-8357.9%——-20794.6%
EPS (Basic)(2.28)(1.72)(0.88)(0.92)(1.08)
EPS (Diluted)(2.28)(1.72)(0.88)(0.92)(1.08)
Weighted Avg Shares27.96M33.94M48.04M58.4M67.4M
Weighted Avg Shares (Diluted)27.96M33.94M48.04M58.4M67.4M

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.